CureVac's Cvncov Phase 2B/3 Study Data Of CVnCoV Published In Preprints With The Lancet; Significant Protection Was Demonstrated, Protection Against Moderate To Severe Disease For This Age Group Was 77%, 100% Protection Against Hospitalization Or Death